Histopathological Changes in
Androgen-Deprived Localized
Prostatic Cancer

Hellström, Mats; Häggman, Mikael; Brändstedt, S.; Torre, Manuel de la; Pedersen, Katja Venborg; Jarlsfeldt, I; Wijkström, Hans; Büsch, Christopher

doi:10.1159/000474350

Cited by 51 publications

(28 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neoadjuvant pre-operative androgen deprivation in patients with localized prostate cancer is associated with prostate cancer, only areas judged and marked as cancerous tissue were examined. Basal cells were not stained extensive histopathological changes in benign and malignant tissues [9]. The marked decline in PSA in serum immunohistochemically to indicate normal glands.…”

Section: Resultsmentioning

confidence: 94%

“…transforming growth factor (TGF-b), is still largely speculative [24]. tions could not be graded because there were marked histopathological changes [9] in the surgical specimens The composition of the stroma, i.e. the connective tissue to smooth muscle ratio, was not affected by the altered from the hormone-treated patients.…”

Section: Resultsmentioning

confidence: 99%

“…To evaluate the possible effects on stromal tissue, which those in group 1 but none of those in group 2 had clinical T3 tumours. There was no difference in the also contains androgen receptors [7], we measured tissue distribution of tumour grade between the groups; detailed information about the patients is reported elsewhere [1,6,9,10].…”

Section: Methodsmentioning

confidence: 99%

“…The tumour areas were measured in all sections and the tumour volumes were calculated using of all pixels representing cancer cells to the total number of pixels was used to define tumour density. a computer-assisted planimetric method [9,11].…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Effect of androgen deprivation on epithelial and mesenchymal tissue components in localized prostate cancer

Hellström

Wester

Brändstedt

et al. 1997

British Journal of Urology

View full text Add to dashboard Cite

Objective To measure the area distribution of epithelial and mesenchymal components in the prostate of patients with localized prostate cancer after temporary androgen deprivation. Patients and methods Surgical specimens from 38 patients treated with the gonadotrophin‐releasing hormone agonist triptorelin for 3 months before radical prostatectomy were examined (group 1). Specimens from a second group of 54 patients who underwent the same surgical procedure with no prior therapy were used as controls (group 2). The specimens were serially step‐sectioned and whole‐mount tissue sections prepared. The epithelial, smooth muscle and connective tissue components were stained separately with immunohistochemical and histochemical techniques, respectively. Using colour‐based image analyses, the tissue components were classified into three categories, displayed in different colours. The percentage of tumour areas occupied by cancer epithelial cells, connective tissue and smooth muscle was determined. Results In specimens from group 1, the cancer epithelium was sparse and scattered throughout the tumour area. A mean (sd) of 21 (11)% of the area was occupied by cancer cells, compared with 40 (11)% in the corresponding material from group 2 (P<0.001). The connective tissue/smooth muscle ratio in stroma (about 1:1) was similar in both groups. Conclusions Neoadjuvant hormone treatment of patients with localized prostate cancer was associated with a marked reduction in tumour density and thus in the total amount of cancer epithelium.

show abstract

Section: Resultsmentioning

confidence: 94%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Effect of androgen deprivation on epithelial and mesenchymal tissue components in localized prostate cancer

Hellström

Wester

Brändstedt

et al. 1997

British Journal of Urology

View full text Add to dashboard Cite

show abstract

“…For reprints and all correspondence: Osamu Maeda, Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka 537, Japan Abbreviations: PI, proliferative index; AI, apoptotic index; LHRH, luteinizing hormone-releasing hormone; TdT, terminal deoxynucleotidyl transferase; POST-S, radical prostatectomy specimens; PRE-S, biopsy specimens fibromuscular component, nuclear pyknosis and cytoplasmic vacuolization of tumor cells are observed in the prostatic tissue (2)(3)(4). However, it is difficult to distinguish these types of pathologic degeneration caused by endocrine therapy from residual poorly differentiated tumors by routine histopathologic staining (5).…”

Section: Introductionmentioning

confidence: 99%

Adjunctive Value of Cell Proliferation but Not of Apoptosis to Interpret Pathologic Effects on Prostatic Cancer after Neoadjuvant Endocrine Therapy

Maeda

Kinouchi

Meguro

et al. 1998

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Background: The current histological evaluation of the effects of endocrine therapy has difficulty in distinguishing pathologic degeneration caused by androgen ablation from residual poorly differentiated tumor. Therefore, we examined the changes in cell proliferation and apoptosis before and afterendocrine therapy andanalyzed whether they correlated with pathologic effects and histological differentiation. Methods: Between January 1986and December 1995, 52 patients with clinical stage B2 and C prostate cancer underwent radical prostatectomy after neoadjuvant endocrine therapy (median duration 3.8 months). Proliferative andapoptotic activities of pretreatment biopsy specimens and radical prostatectomy specimens were analyzed with MIB-1 monoclonal antibody and in situ end-labeling of fragmented DNA. Results: The mean proliferative index (PI) of radical prostatectomy specimens was significantly lowerthan thatof biopsy specimens (P = 0.000 003) andthe decrease in PIafterendocrine therapy was significantly related to histological differentiation (P = 0.014). There was a weak relationship between the decrease in PI after endocrine therapy and pathologic effects (P = 0.054), while in pathologically effective cases (Grades 2 and 3), three out of 16 (19%) showed a <50% decrease in PI after endocrine therapy, and may be regarded as having poorly differentiated tumors. The mean apoptotic index (AI) of prostatectomy specimens tended to be higher than that of biopsy specimens (P =0.054). The increase in AI after endocrine therapy was not related to histological differentiation and pathologic effects. Conclusion: Pathologic effects caused by endocrine therapy may be in part misled by routine histopathologic staining and the change in PI may help in recognizing the pathologic effects of endocrine therapy and have adjunctive value for the interpretation of the effects of endocrine therapy.

show abstract

Morphologic and lmmunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies

Voorde¹,

Elgamal²,

Poppel³

et al. 1994

Cancer

View full text Add to dashboard Cite

Background. Estramustine phosphate (EMP) and flutamide (FL) were used as reversible preoperative hormonal drugs in the surgical treatment of patients with localized prostate cancer. Methods. The authors descriptive and quantitatively examined the morphologic and immunohistochemical changes in 40 of 200 step‐sectioned radical prostatectomies, obtained after treatment with EMP (25 patients) and with FL (15 patients). Of these, 28 pretreatment needlecore biopsies were available. Results. Every specimen contained adenocarcinoma. Understaging was found in 50% of the cases and a higher Gleason score in 70%. Benign glands underwent atrophy and squamous metaplasia. Treated tumors showed cytoplasmic vacuolization, nuclear pyknosis, fibrosis and lymphocytic infiltrates. The EMP group had an 84% (P < 0.05) higher mean total regression score than the FL group. Estramustine phosphate induced a 56% (P < 0.05) and a 34% decrease in tumoral prostate specific antigen and prostate specific acid phosphatase intensity scores, respectively, versus 29% and 32% after FL. The mean proliferating cell nuclear antigen (PCNA) labeling index and the mean mitotic index of the EMP group were 52% (P < 0.05) and 70% (P < 0.05) lower than those measured in the FL group. Each FL‐treated tumor and 92% of EMP‐treated tumors expressed chromogranin A (ChrA); ChrA labeling correlated significantly with PCNA labeling. Seventy‐six percent of EMP‐treated specimens revealed venous thrombosis. Conclusions. Estramustine phosphate induces important morphologic and immunohistochemical changes in prostate cancer with an apparent decrease of secretory and proliferative activity when compared with FL‐treated tumors. These changes represent pitfalls in the diagnosis and grading of treated carcinomas. Nearly every treated adenocarcinoma of the prostate has neuroendocrine differentiation, showing increasing ChrA labeling with higher tumor stage. A significant correlation between tumor proliferation and neuroendocrine differentiation was noticed in this small cohort of patients. There was a high incidence of periprostatic venous thrombosis after EMP treatment.

show abstract

Histopathological Changes in Androgen-Deprived Localized Prostatic Cancer

Cited by 51 publications

References 12 publications

Effect of androgen deprivation on epithelial and mesenchymal tissue components in localized prostate cancer

Effect of androgen deprivation on epithelial and mesenchymal tissue components in localized prostate cancer

Adjunctive Value of Cell Proliferation but Not of Apoptosis to Interpret Pathologic Effects on Prostatic Cancer after Neoadjuvant Endocrine Therapy

Morphologic and lmmunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies

Contact Info

Product

Resources

About